SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to recent achievements and potential catalysts, including the registration of their Midnight aircraft with the FAA. Community members are actively discussing the company's prospects, particularly its relationship with Japan Airlines and potential military applications, while also debating whether the stock can outperform its competitor, Joby Aviation. Some investors believe upcoming events, like piloted VTOL flights and air shows, could trigger a significant price increase.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision, encapsulated by the phrase "Like Bitcoin But Way Higher". Active discussions involve the project's roadmap and potential, with community members emphasizing its cultural relevance and potential for growth, particularly regarding developments in the broader cannabis industry.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors grapple with recent price action, despite strong earnings, and debate whether the company is oversold or poised for further declines. Community discussions revolve around concerns about capital expenditures and AI investments, while some anticipate a rebound. Others point to potential catalysts like a Gemini partnership or the trial decision, as well as competition from Apple in AI glasses.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as the stock experiences a significant sell-off, sparking debates among investors about potential causes, including a Bloomberg article referencing a competitor's GLP-1 product offering. The community is actively discussing whether the sell-off is an overreaction and if the company's fundamentals remain strong, while also eyeing potential bounce-back opportunities. Some traders speculate about algo manipulation and stop-loss triggers amidst the volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its investigational drug Vepdegestrant.Wells Fargo believes Pfizer's (PFE) waning interest in Vepdegestrant could lead to Arvinas getting it back, but given where the stock is trading, this seems priced in. The firm noted that Arvinas won't launch the drug solo and added that with runway to the second half of 2028, focus shifts to its early-stage pipeline, which can create value.Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of Vepdegestrant in July 2021. Wells lowered its price target on <a href="https://stocktwits.com/symbol/ARVN">Arvinas</a> to $16 from $19 while keeping an ‘Overweight’ rating on the shares.&nbsp;On Stocktwits, retail sentiment around Arvinas fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_10_00_16_AM_png_a0b59de82a.webp" alt="ARVN's Sentiment Meter and Message Volume as of 10 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>ARVN's Sentiment Meter and Message Volume as of 10 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright, however, raised its price target on Arvinas to $24 from $18 while keeping a ‘Buy’ rating on the shares. The firm sees a path forward for Vepdegestrant and cited the company's pipeline development and progress for the target increase.Arvinas and its partner Pfizer submitted a new drug application for Vepdegestrant to the U.S. Food and Drug Administration in June for the treatment of certain types of advanced or metastatic breast cancer previously treated with endocrine-based therapy.The application was based on data from a late-stage trial that evaluated Vepdegestrant versus the popular breast cancer medicine Fulvestrant. While the trial demonstrated improvement in median progression-free survival (PFS) compared to Fulvestrant, it did not reach statistical significance.In the second quarter, Arvinas recorded a revenue of $22.4 million, down from $76.5 million in the corresponding quarter of 2024. The company pegged the drop in part to a fall in revenue from the agreement with Pfizer related to the removal of certain late-stage combination trials of Vepdegestrant with Pfizer’s investigational drugs from the development plan.ARVN stock is down by 68% this year and by about 75% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-warns-higher-us-tariff-impact-for-fy26/chrmEbQRdd6">Toyota Warns Higher US Tariff Impact For FY26: Retail Sees No Reason To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach

While Wells Fargo remains pessimistic on Vepdegestrant’s future, H.C. Wainwright is hopeful. 

Equity

While Wells Fargo remains pessimistic on Vepdegestrant’s future, H.C. Wainwright is hopeful. 


Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales. 

Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of +3.45% and -53.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Arvinas Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$9.72
Prev Close	$9.27
Open	$9.40
Dividend Yield	0.00%
50-Day Moving Average	$7.59
Beta	1.42
Avg. Volume	2.08M
PE Ratio	-1.79

52-Week High	$29.61
52-Week Low	$5.90
Market Capitalization	$680.58M
EPS (Annual)	-$2.77
Price to Book	1.11
Revenue Per Employee	$612,558.14
Enterprise Value/EBITDA	N/A

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARVN News

ARVN Arvinas Inc